Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Block Inc (XYZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Block Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Block Inc trades at $76.08 (market cap $46.16B). The key difference: Block Inc is far larger — about 10.3× ACADIA Pharmaceuticals Inc.'s market cap, and Block Inc is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | XYZ | |
|---|---|---|
Market Cap | $4.49B | $46.16B |
Sector | Health | Technology |
52-Week High | $28.06 | $81.11 |
52-Week Low | $20.06 | $49.04 |
Enterprise Value | $3.69B | $41.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
XYZ (Block, Inc.) trades at $77.56, down 1.61% today, with a bullish technical signal from moving averages and strong analyst consensus (74% buy ratings). Recent earnings show mixed results with Q1 2026 beating expectations, while cash flow turned negative in 2025 due to heavy investing. The company continues expanding its Square platform through AI integrations and enterprise partnerships, positioning for growth in digital payments.
Outlook remains positive with a $87.71 consensus price target, though high P/E of 61.66 and declining net income margins pose valuation concerns. Key risks include execution on AI initiatives and competitive pressure in fintech. Institutional sentiment is supportive, but investors should monitor Q2 2026 earnings due August 5, 2026 for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
